Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Interest & Investment Income (2020 - 2022)

Terns Pharmaceuticals' Interest & Investment Income history spans 3 years, with the latest figure at $1.3 million for Q4 2022.

  • For Q4 2022, Interest & Investment Income rose 2314.55% year-over-year to $1.3 million; the TTM value through Dec 2022 reached $2.1 million, up 1141.18%, while the annual FY2025 figure was $14.6 million, 9.8% up from the prior year.
  • Interest & Investment Income reached $1.3 million in Q4 2022 per TERN's latest filing, up from $499000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.3 million in Q4 2022 to a low of $1000.0 in Q3 2020.
  • Average Interest & Investment Income over 3 years is $194583.3, with a median of $52500.0 recorded in 2020.
  • The largest YoY upside for Interest & Investment Income was 4800.0% in 2021 against a maximum downside of 78.0% in 2021.
  • A 3-year view of Interest & Investment Income shows it stood at $2000.0 in 2020, then skyrocketed by 2650.0% to $55000.0 in 2021, then surged by 2314.55% to $1.3 million in 2022.
  • Per Business Quant, the three most recent readings for TERN's Interest & Investment Income are $1.3 million (Q4 2022), $499000.0 (Q3 2022), and $214000.0 (Q2 2022).